Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition

Phase 1 Completed 40 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-387 in healthy volunteers under fasting condition.

Timeline

Start: 2023-02-01
Primary completion: 2023-02-11
Completion: 2023-02-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-387	Unknown	—	—
Subject	D484	Unknown	—	—

Indications

No indication recorded.